Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27876904 | 0.83 | KMT2A (0.43) | MAPTGAAALDH1A1HTTHSD17B10 | |
| SCHEMBL17868331 | 0.80 | RXFP1 (0.48) | MAPTALDH1A1HTTCCNA2CDK2 | |
| SCHEMBL27911140 | 0.79 | MAPK1 (0.50) | MAPTALDH1A1KMT2AMAPK14GSK3A | |
| SCHEMBL28960724 | 0.77 | GABRP (0.36) | MAPTGAAALDH1A1KMT2ATDP1 | |
| SCHEMBL28928002 | 0.74 | JAK2 (0.41) | MAPTGAAALDH1A1HSD17B10CCNA2 | |
| SCHEMBL31317518 | 0.74 | CNR2 (0.54) | MAPTGAAALDH1A1HTTHSD17B10 | |
| SCHEMBL27822677 | 0.74 | CNR2 (0.54) | MAPTGAAALDH1A1HTTHSD17B10 | |
| SCHEMBL27460220 | 0.74 | ALDH1A1 (0.45) | MAPTGAAALDH1A1HTTHSD17B10 | |
| SCHEMBL2386548 | 0.74 | NNMT (0.36) | MAPTGAAALDH1A1KMT2ARAB9A | |
| SCHEMBL28489651 | 0.72 | ALDH1A1 (0.65) | MAPTGAAALDH1A1HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676724-B2 | Cyanoquinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2017-06-13 | — | — | US | disclosed |
| CN-102933578-B | Cyano-quinoline derivatives | 天津和美生物技术有限公司 | 2016-09-07 | — | — | CN | disclosed |
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2016-06-30 | — | — | US | disclosed |
| CN-102933578-A | Cyanoquinoline derivatives | TIANJIN HEMAY BIO TECH CO LTD | 2013-02-13 | — | — | CN | disclosed |
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| CN-1391563-A | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185728-A1 | CYANOQUINOLINE DERIVATIVES | CBR3, CYP3A4, CDK1 | MAPT 43/4885GAA 2677/4885ALDH1A1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.